MCE RedChemExpress

Product Data Sheet

Crolibulin

Cat. No.: HY-13603

CAS No.: 1000852-17-4 $\label{eq:casho} \mbox{Molecular Formula:} \qquad \mbox{C_{18}H}_{17}\mbox{$BrN}_4\mbox{$O_3$}$

Molecular Weight: 417.26

Target: Microtubule/Tubulin; Apoptosis

Pathway: Cell Cycle/DNA Damage; Cytoskeleton; Apoptosis

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

$$H_2N$$
 O
 NH_2
 $NH_$

SOLVENT & SOLUBILITY

In Vitro

DMSO: 125 mg/mL (299.57 mM; Need ultrasonic and warming)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3966 mL	11.9829 mL	23.9659 mL
	5 mM	0.4793 mL	2.3966 mL	4.7932 mL
	10 mM	0.2397 mL	1.1983 mL	2.3966 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	Crolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicity ^{[1][2][3]} .		
IC ₅₀ & Target	Tubulin polymerization $^{[1]}$		
In Vitro	Crolibulin shows significant cytotoxic activity against HT-29 cells, with an IC ₅₀ of 0.52 μ M ^[2] . Crolibulin is active against various experimental tumors and exhibit potent inhibition of mitosis at the G2/M stage ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

CUSTOMER VALIDATION

• Biochem Biophys Res Commun. 2019 Apr 2;511(2):381-386.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Kalmuk J, et al. Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget. 2015 Sep 15;6(27):24376-92.
- [2]. Zhai X, et al. Discovery and Optimization of Novel 5-Indolyl-7-arylimidazo[1,2-a]pyridine-8-carbonitrile Derivatives as Potent Antitubulin Agents Targeting Colchicine-binding Site. Sci Rep. 2017 Feb 27;7:43398.
- [3]. S. P. Anthony, et al. EPC2407, a new beta-tubulin vascular disrupting agent with potent apoptosis and cell growth inhibition. Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007) 14043-14043.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA